- Home
- CYH vs NBP Comparison
CYH vs NBP Comparison
Compare CYH & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | NBP |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 503.8M |
| IPO Year | 1991 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CYH | NBP |
|---|---|---|
| Price | $3.44 | $3.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $3.56 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.9M | 632.4K |
| Earning Date | 02-18-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $12,644,000,000.00 | N/A |
| Revenue This Year | $0.04 | N/A |
| Revenue Next Year | $0.86 | N/A |
| P/E Ratio | $1.37 | ★ N/A |
| Revenue Growth | ★ 0.74 | N/A |
| 52 Week Low | $2.24 | $0.60 |
| 52 Week High | $4.47 | $6.79 |
Technical Indicators
Market Signals| Indicator | CYH | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 38.21 |
| Support Level | $3.02 | $3.29 |
| Resistance Level | $3.19 | $3.74 |
| Average True Range (ATR) | 0.17 | 0.25 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 83.05 | 18.05 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.